SCHEMBL7796811

SCHEMBL7796811

CN1CCSC(Cc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 4/20 0.46
GAA P10253 5/20 0.43
TSHR P16473 5/20 0.43
LMNA P02545 3/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
HPGD P15428 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPK1 P28482 2/20 0.38
BLM P54132 2/20 0.38
ATM Q13315 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8532155 0.86 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL7803041 0.81 ITGB1 (0.41) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL8336241 0.80 GSR (0.44) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL7804597 0.79 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL7803501 0.79 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL7804601 0.79 GAA (0.48) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL7703145 0.76 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL8532773 0.76 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTGAATSHR
Hydrochloric Acid SCHEMBL7803042 0.76 MAOB (0.35) ALDH1A1KDM4EMAPTGAATSHR
SCHEMBL8933311 0.74 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010018437-A1 NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS PANETTA JILL (US) 2001-08-30 US claimed
US-5981523-A ADMINISTERING THIOMORPHOLINONE COMPOUND TO THE PATIENT SUFFERING FROM MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1999-11-09 US claimed
EP-0779282-A1 Thiomorpholinone compounds for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1997-06-18 EP claimed
US-20010018437-A1 NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS PANETTA JILL (US) 2001-08-30 US disclosed
US-5981523-A ADMINISTERING THIOMORPHOLINONE COMPOUND TO THE PATIENT SUFFERING FROM MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1999-11-09 US disclosed
EP-0779282-A1 Thiomorpholinone compounds for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1997-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018437-A1 NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS TXNRD3, TXNRD2, CTH ALDH1A1 2827/4885KDM4E 1072/4885MAPT 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.